Dieter Egli’s research in the NYSCF laboratory currently focuses on the generation of therapeutically relevant cells for diabetes. His work has relevance for the use of stem cells to study disease, screen for new drugs, and cell replacement therapy. His research creating patient-specific stem cells using the DNA of patients with type 1 diabetes, first published in Nature in October 2011, was named the #1 Medical Breakthrough of 2011 by TIME magazine, which also named him one of 2011’s People Who Mattered. Dr. Egli earned his PhD at the University of Zurich, Switzerland. He received his postdoctoral training in the laboratory of Kevin Eggan at the Department of Stem Cell and Regenerative Biology, Harvard University, studying reprogramming after nuclear transfer. Dr. Egli is also an Adjunct Associate Research Scientist in the Division of Molecular Genetics, Department of Pediatrics, Columbia University, and has a collaborative relationship with Columbia’s Naomi Berrie Diabetes Center.